Literature DB >> 21917944

The assembly-activating protein promotes capsid assembly of different adeno-associated virus serotypes.

F Sonntag1, K Köther, K Schmidt, M Weghofer, C Raupp, K Nieto, A Kuck, B Gerlach, B Böttcher, O J Müller, K Lux, M Hörer, J A Kleinschmidt.   

Abstract

Adeno-associated virus type 2 (AAV2) capsid assembly requires the expression of a virally encoded assembly-activating protein (AAP). By providing AAP together with the capsid protein VP3, capsids are formed that are composed of VP3 only. Electron cryomicroscopy analysis of assembled VP3-only capsids revealed all characteristics of the wild-type AAV2 capsids. However, in contrast to capsids assembled from VP1, VP2, and VP3, the pores of VP3-only capsids were more restricted at the inside of the 5-fold symmetry axes, and globules could not be detected below the 2-fold symmetry axes. By comparing the capsid assembly of several AAV serotypes with AAP protein from AAV2 (AAP-2), we show that AAP-2 is able to efficiently stimulate capsid formation of VP3 derived from several serotypes, as demonstrated for AAV1, AAV2, AAV8, and AAV9. Capsid formation, by coexpressing AAV1-, AAV2-, or AAV5-VP3 with AAP-1, AAP-2, or AAP-5 revealed the ability of AAP-1 and AAP-2 to complement each other in AAV1 and AAV2 assembly, whereas for AAV5 assembly more specific conditions are required. Sequence alignment of predicted AAP proteins from the known AAV serotypes indicates a high degree of homology of all serotypes to AAP-2 with some divergence for AAP-4, AAP-5, AAP-11, and AAP-12. Immunolocalization of assembled capsids from different serotypes confirmed the preferred nucleolar localization of capsids, as observed for AAV2; however, AAV8 and AAV9 capsids could also be detected throughout the nucleus. Taken together, the data show that AAV capsid assembly of different AAV serotypes also requires the assistance of AAP proteins.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21917944      PMCID: PMC3209379          DOI: 10.1128/JVI.05359-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  34 in total

1.  Adenovirus protein V induces redistribution of nucleolin and B23 from nucleolus to cytoplasm.

Authors:  D A Matthews
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  Characterization of the transcription profile of adeno-associated virus type 5 reveals a number of unique features compared to previously characterized adeno-associated viruses.

Authors:  Jianming Qiu; Ramnath Nayak; Gregory E Tullis; David J Pintel
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy.

Authors:  Qing Xie; Weishu Bu; Smita Bhatia; Joan Hare; Thayumanasamy Somasundaram; Arezki Azzi; Michael S Chapman
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-22       Impact factor: 11.205

4.  UCSF Chimera--a visualization system for exploratory research and analysis.

Authors:  Eric F Pettersen; Thomas D Goddard; Conrad C Huang; Gregory S Couch; Daniel M Greenblatt; Elaine C Meng; Thomas E Ferrin
Journal:  J Comput Chem       Date:  2004-10       Impact factor: 3.376

5.  Assembly of adeno-associated virus.

Authors:  M W Myers; B J Carter
Journal:  Virology       Date:  1980-04-15       Impact factor: 3.616

6.  Electron cryo-microscopy and image reconstruction of adeno-associated virus type 2 empty capsids.

Authors:  S Kronenberg; J A Kleinschmidt; B Böttcher
Journal:  EMBO Rep       Date:  2001-11       Impact factor: 8.807

7.  Alternative polyadenylation of adeno-associated virus type 5 RNA within an internal intron is governed by both a downstream element within the intron 3' splice acceptor and an element upstream of the P41 initiation site.

Authors:  Jianming Qiu; Ramnath Nayak; David J Pintel
Journal:  J Virol       Date:  2004-01       Impact factor: 5.103

8.  Helper virus-free, optically controllable, and two-plasmid-based production of adeno-associated virus vectors of serotypes 1 to 6.

Authors:  Dirk Grimm; Mark A Kay; Juergen A Kleinschmidt
Journal:  Mol Ther       Date:  2003-06       Impact factor: 11.454

9.  Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy.

Authors:  Guang-Ping Gao; Mauricio R Alvira; Lili Wang; Roberto Calcedo; Julie Johnston; James M Wilson
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-21       Impact factor: 11.205

10.  Clades of Adeno-associated viruses are widely disseminated in human tissues.

Authors:  Guangping Gao; Luk H Vandenberghe; Mauricio R Alvira; You Lu; Roberto Calcedo; Xiangyang Zhou; James M Wilson
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

View more
  69 in total

1.  Establishment of a High-Yield Recombinant Adeno-Associated Virus/Human Bocavirus Vector Production System Independent of Bocavirus Nonstructural Proteins.

Authors:  Ziying Yan; Wei Zou; Zehua Feng; Weiran Shen; Soo Yeun Park; Xuefeng Deng; Jianming Qiu; John F Engelhardt
Journal:  Hum Gene Ther       Date:  2019-01-31       Impact factor: 5.695

2.  Mapping a neutralizing epitope onto the capsid of adeno-associated virus serotype 8.

Authors:  Brittney L Gurda; Christina Raupp; Ruth Popa-Wagner; Matthias Naumer; Norman H Olson; Robert Ng; Robert McKenna; Timothy S Baker; Jürgen A Kleinschmidt; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2012-05-16       Impact factor: 5.103

3.  OneBac: platform for scalable and high-titer production of adeno-associated virus serotype 1-12 vectors for gene therapy.

Authors:  Mario Mietzsch; Sabrina Grasse; Catherine Zurawski; Stefan Weger; Antonette Bennett; Mavis Agbandje-McKenna; Nicholas Muzyczka; Sergei Zolotukhin; Regine Heilbronn
Journal:  Hum Gene Ther       Date:  2014-01-23       Impact factor: 5.695

4.  Limitations of encapsidation of recombinant self-complementary adeno-associated viral genomes in different serotype capsids and their quantitation.

Authors:  Yuan Wang; Chen Ling; Liujiang Song; Lina Wang; George V Aslanidi; Mengqun Tan; Changquan Ling; Arun Srivastava
Journal:  Hum Gene Ther Methods       Date:  2012-08       Impact factor: 2.396

Review 5.  Parvovirus diversity and DNA damage responses.

Authors:  Susan F Cotmore; Peter Tattersall
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-02-01       Impact factor: 10.005

Review 6.  Engineering adeno-associated viruses for clinical gene therapy.

Authors:  Melissa A Kotterman; David V Schaffer
Journal:  Nat Rev Genet       Date:  2014-05-20       Impact factor: 53.242

7.  Establishment of a novel cell line for the enhanced production of recombinant adeno-associated virus vectors for gene therapy.

Authors:  Stifani Satkunanathan; Jun Wheeler; Robin Thorpe; Yuan Zhao
Journal:  Hum Gene Ther       Date:  2014-09-11       Impact factor: 5.695

8.  Structure and dynamics of adeno-associated virus serotype 1 VP1-unique N-terminal domain and its role in capsid trafficking.

Authors:  Balasubramanian Venkatakrishnan; Joseph Yarbrough; John Domsic; Antonette Bennett; Brian Bothner; Olga G Kozyreva; R Jude Samulski; Nicholas Muzyczka; Robert McKenna; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2013-02-20       Impact factor: 5.103

Review 9.  Pre-existing anti-adeno-associated virus antibodies as a challenge in AAV gene therapy.

Authors:  Vedell Louis Jeune; Jakob A Joergensen; Roger J Hajjar; Thomas Weber
Journal:  Hum Gene Ther Methods       Date:  2013-04-03       Impact factor: 2.396

10.  Cryo-electron Microscopy Reconstruction and Stability Studies of the Wild Type and the R432A Variant of Adeno-associated Virus Type 2 Reveal that Capsid Structural Stability Is a Major Factor in Genome Packaging.

Authors:  Lauren M Drouin; Bridget Lins; Maria Janssen; Antonette Bennett; Paul Chipman; Robert McKenna; Weijun Chen; Nicholas Muzyczka; Giovanni Cardone; Timothy S Baker; Mavis Agbandje-McKenna
Journal:  J Virol       Date:  2016-09-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.